Abstract
For the first time in Russia a comparative study of chromogranin A (CgA) and chromogranin B (CgB) in neuroendocrine tumors (NETs) of the pancreas was performed. We examined 50 primary patients with pancreatic NETs and 42 healthy people. The determination of CgA and CgB was performed in blood serum using standard enzyme-linked immunoassay test-systems (Chromogranin A NEOLISA, Eurodiagnostica; Human Chromogranin B, USCN). The levels of CgA and CgB in pancreatic NETs significantly differed from the control group. There was found the association between CgA levels and the dissemination of the process, while CgB demonstrated the properties of a marker independent from the tumor dissemination. The diagnostic sensitivity of CgA was 76 %, CgB – 68 %. Complex determination of CgA and CgB enhanced the diagnostic sensitivity to 84 %. Our data indicate the potential usefulness of complex CgA and CgB in the diagnosis of pancreatic NETs.
Highlights
We examined 50 primary patients with pancreatic neuroendocrine tumors (NETs) and 42 healthy people
The determination of chromogranin A (CgA) and chromogranin B (CgB) was performed in blood serum using standard enzyme-linked immunoassay test-systems (Chromogranin A NEOLISA, Eurodiagnostica; Human Chromogranin B, USCN)
The levels of CgA and CgB in pancreatic NETs significantly differed from the control group
Summary
Н. В. Любимова, д. б. н., в. н. с. лаборатории Ю. С. Тимофеев, к. м. н., врач лаборатории А. В. Лебедева, м. н. с. лаборатории Н. Е. Кушлинский, д. м. н., проф., акад. РАН, зав. лабораторией Лаборатория клинической биохимии ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава России, г. Москва
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call